01 octubre 2013

CIRCULATION: CARDIOVASCULAR INTERVENTIONS: Risk of Coronary Artery Compression Among Patients Referred for Transcatheter Pulmonary Valve Implantation

Brian H. Morray, MD, Doff B. McElhinney, MD, John P. Cheatham, MD, Evan M. Zahn, MD, Darren P. Berman, MD, Patrick M. Sullivan, MD, James E. Lock, MD and Thomas K. Jones, MD

Background—The Melody transcatheter pulmonary valve (TPV) was approved for implantation in obstructed right ventricular outflow tract conduits in 2010 after a multicenter trial demonstrating improvements in conduit obstruction, regurgitation, and right ventricular pressure. A recognized risk and contraindication to TPV implantation is the demonstration of coronary artery (CA) compression during balloon angioplasty or stent placement in the overlying conduit. This study is the first to characterize the risk of CA compression in this population.

01 octubre 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Remote Ischemic Post-Conditioning of the Lower Limb During Primary Percutaneous Coronary Intervention Safely Reduces Enzymatic Infarct Size in Anterior Myocardial Infarction. A Randomized Controlled Trial

Gabriele Crimi, MD∗; Silvia Pica, MD∗; Claudia Raineri, MD∗; Ezio Bramucci, MD∗; Gaetano M. De Ferrari, MD∗; Catherine Klersy, MD, MSc‡; Marco Ferlini, MD∗; Barbara Marinoni, MD∗; Alessandra Repetto, MD∗; Maurizio Romeo, MD†; Vittorio Rosti, MD§; Margherita Massa, PhD§; Arturo Raisaro, MD∗; Sergio Leonardi, MD, MHS∗; Paolo Rubartelli, MD†; Luigi Oltrona Visconti, MD∗; Maurizio Ferrario, MD∗

Objectives This study sought to evaluate whether remote ischemic post-conditioning (RIPC) could reduce enzymatic infarct size in patients with anterior ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (pPCI).

01 noviembre 2013

CANADIAN JOURNAL OF CARDIOLOGY. Percutaneous Paravalvular Leak Reduction: Procedural and Long-term Clinical Outcomes

Stéphane Noble, MD , E. Marc Jolicoeur, MD, MSc, MHS , Arsène Basmadjian, MD, MSc , Sylvie Levesque, MSc , Anna Nozza, MSc , Jeannot Potvin, MD , Jacques Crépeau, MD , Réda Ibrahim, MD

Background: Significant paravalvular leak (PVL) after prosthetic replacement can result in hemolysis and/or congestive heart failure (CHF). Percutaneous PVL reduction (PPVR) represents an alternative to repeat surgery for a selected population. The purpose of this study was to assess the procedural and long-term clinical efficacy of percutaneous PPVR and its effect on survival free of rehospitalization for CHF, surgical reintervention, and death.

01 noviembre 2013

AMERICAN HEART JOURNAL. Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: Rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in Uncertain DES Candidates study

Marco Valgimigli, MD, PhD , Athanasios Patialiakas, MD , Attila Thury, MD, PhD , Salvatore Colangelo, MD , Gianluca Campo, MD , Matteo Tebaldi, MD , Imre Ungi, MD, PhD , Stefano Tondi, MD , Marco Roffi, MD , Alberto Menozzi, MD, PhD , Nicoletta de Cesare, MD , Roberto Garbo, MD , Emanuele Meliga, MD , Luca Testa, MD, PhD , Henrique M. Gabriel, MD , Flavio Airoldi, MD , Marco Ferlini, MD , Francesco Liistro, MD , Antonio Dellavalle, MD , Pascal Vranckx, MD , Carlo Briguori, MD, PhD

Background: The use of drug-eluting stent (DES) instead of bare-metal stent (BMS) in patients at high stent thrombosis or bleeding risk as well as in those at low restenosis risk (ie, uncertain DES candidates) remains a matter of debate. Zotarolimus-Eluting Endeavor Sprint stent (E-ZES) (Santa Rosa, CA) is a hydrophilic polymer-based second-generation device with unique drug fast-release profile, which may allow for a shorter dual antiplatelet therapy (DAPT) duration without safety concerns.

01 octubre 2013

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Increased Thin-Cap Neoatheroma and Periprocedural Myocardial Infarction in Drug-Eluting Stent Restenosis. Multimodality Intravascular Imaging of Drug-Eluting and Bare-Metal Stents

Ziad A. Ali, MD, DPhil, Tomasz Roleder, MD, Jagat Narula, MD, PhD, Bibhu D. Mohanty, MD, Usman Baber, MD, Jason C. Kovacic, MD, PhD, Gary S. Mintz, MD, Fumiyuki Otsuka, MD, PhD, Stephen Pan, MD, Renu Virmani, MD, Samin K. Sharma, MD, Pedro Moreno, MD and Annapoorna S. Kini, MD

Background—Re-endothelialization is delayed after drug-eluting stent (DES) implantation. In this setting, neointima is more prone to become lipid laden and develop neoatherosclerosis (NA), potentially increasing plaque vulnerability.

01 octubre 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Prognostic Value of Microvascular Resistance Index Immediately After Primary Percutaneous Coronary Intervention on Left Ventricular Remodeling in Patients With Reperfused Anterior Acute ST-Segment Elevation Myocardial Infarction

Hironori Kitabata, MD, PhD; Takashi Kubo, MD, PhD; Kohei Ishibashi, MD; Kenichi Komukai, MD; Takashi Tanimoto, MD, PhD; Yasushi Ino, MD, PhD; Manabu Kashiwagi, MD; Yuichi Ozaki, MD; Yasutsugu Shiono, MD; Kunihiro Shimamura, MD; Makoto Orii, MD; Kumiko Hirata, MD, PhD; Atsushi Tanaka, MD, PhD; Toshio Imanishi, MD, PhD; Takashi Akasaka, MD, PhD

Objectives: This study sought to investigate the relationship between the degree of microvascular dysfunction assessed by a dual-sensor guidewire (pressure and Doppler velocity) and left ventricular (LV) remodeling after successful primary percutaneous coronary intervention (PPCI) for a first anterior acute myocardial infarction (AMI).

01 noviembre 2013

JACC. In Vivo Diagnosis of Plaque Erosion and Calcified Nodule in Patients With Acute Coronary Syndrome by Intravascular Optical Coherence Tomography

Haibo Jia, MD, PhD∗; Farhad Abtahian, MD, PhD†; Aaron D. Aguirre, MD, PhD‡; Stephen Lee, MD§; Stanley Chia, MD‖; Harry Lowe, MBChB, PhD¶; Koji Kato, MD, PhD†; Taishi Yonetsu, MD†; Rocco Vergallo, MD†; Sining Hu, MD∗; Jinwei Tian, MD, PhD∗; Hang Lee, PhD#; Seung-Jung Park, MD, PhD∗∗; Yang-Soo Jang, MD, PhD††; Owen C. Raffel, MD‡‡; Kyoichi Mizuno, MD, PhD§§; Shiro Uemura, MD, PhD‖‖; Tomonori Itoh, MD¶¶; Tsunekazu Kakuta, MD##; So-Yeon Choi, MD, PhD∗∗∗; Harold L. Dauerman, MD†††; Abhiram Prasad, MD‡‡‡; Catalin Toma, MD§§§; Iris McNulty, RN†; Shaosong Zhang, MD, PhD‖‖‖; Bo Yu, MD, PhD∗; Valentine Fuster, MD, PhD¶¶¶; Jagat Narula, MD, PhD¶¶¶; Renu Virmani, MD###; Ik-Kyung Jang, MD, PhD†

Objectives: The aim of this study was to characterize the morphological features of plaque erosion and calcified nodule in patients with acute coronary syndrome (ACS) by optical coherence tomography (OCT).

01 octubre 2013

THE LANCET. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial

Clemens von Birgelen PhD, Hanim Sen MD a, Ming Kai Lam MD a, Peter W Danse PhD c, Gillian A J Jessurun PhD d, Raymond W M Hautvast PhD e, Gert K van Houwelingen MD a, Alexander R Schramm MD d, R Melvyn Tjon Joe Gin MD c, Johannes W Louwerenburg MD a, Frits H A F de Man PhD a, Martin G Stoel PhD a, Marije M Löwik PhD a, Gerard C M Linssen PhD f, Salah A M Saïd PhD f, Mark B Nienhuis PhD g, Patrick M J Verhorst PhD a, Mounir W Z Basalus PhD a, Carine J M Doggen PhD b, Kenneth Tandjung MD

Background: Third-generation, permanent-polymer-based drug-eluting stents with novel, flexible designs might be more easily delivered than previous generations of stents in complex coronary lesions, but might be less longitudinally stable. We aimed to assess the safety and efficacy in all-comer patients of two third-generation stents that are often used clinically, but that have not yet been compared, and one of which has not previously been assessed in a randomised trial.

01 octubre 2013

CIRCULATION. Relationship Between the Magnitude of Reduction in Mitral Regurgitation Severity and Left Ventricular and Left Atrial Reverse Remodeling After MitraClip Therapy

Paul A. Grayburn, MD; Elyse Foster, MD; Chithra Sangli; Neil J. Weissman, MD; Joseph Massaro, PhD; Donald G. Glower, MD; Ted Feldman, MD; Laura Mauri, MD

Background—MitraClip has been shown to reduce mitral regurgitation (MR) severity safely but to a lesser degree than surgery. No data exist on the magnitude of MR reduction necessary to reverse left ventricular (LV) and left atrial (LA) dilation in patients with severe MR. Therefore, an analysis was performed to evaluate the relationship between MR reduction and LV and LA volumes after MitraClip therapy.

01 octubre 2013

JACC: CARDIOVASCULAR INTERVENTIONS. Serial Assessment of Vessel Interactions After Drug-Eluting Stent Implantation in Unprotected Distal Left Main Coronary Artery Disease Using Frequency-Domain Optical Coherence Tomography

Yusuke Fujino, MD∗; Guilherme F. Attizzani, MD∗; Hiram G. Bezerra, MD, PhD∗; Wei Wang, PhD∗; Satoko Tahara, MD, PhD†; Hirosada Yamamoto, MD∗; Daniel Chamie, MD∗; Tomoaki Kanaya, MD∗; Emile Mehanna, MD∗; Kensuke Takagi, MD†; Sunao Nakamura, MD, PhD†; Marco A. Costa, MD, PhD∗

Objectives: This study sought to assess stent-vessel interactions after drug-eluting stent (DES) implantation in unprotected left main coronary artery (ULM) by frequency-domain optical coherence tomography (FD-OCT).

01 noviembre 2013

EUROPEAN HEART JOURNAL. Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristics

Masataka Nakano1, Fumiyuki Otsuka1, Kazuyuki Yahagi1, Kenichi Sakakura1, Robert Kutys1, Elena R. Ladich1, Aloke V. Finn2, Frank D. Kolodgie1 and Renu Virmani1,*

Aims Restenosis in drug-eluting stents (DESs) occurs infrequently, however, it remains a pervasive clinical problem. We interrogated our autopsy registry to determine the underlying mechanisms of DES restenosis, and further we investigated the neointimal characteristics of DESs and compared with bare metal stents (BMSs).

01 septiembre 2013

THE LANCET. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials

Dr Subodh Verma MD, Michael E Farkouh MD e f h, Bobby Yanagawa MD g, David H Fitchett MD b e h, Muhammad R Ahsan MD a, Prof Marc Ruel MD l, Sachin Sud MD h m, Milan Gupta MD a e h n, Shantanu Singh k, Nandini Gupta MD a l, Asim N Cheema MD b e h, Prof Lawrence A Leiter MD c e h i, Paul W M Fedak MD o, Hwee Teoh PhD a c e, David A Latter MD a e g, Prof Valentin Fuster MD p q, Dr Jan O Friedrich MD

Background: The choice between coronary artery bypass surgery (CABG) and percutaneous coronary intervention (PCI) for revascularisation in patients with diabetes and multivessel coronary artery disease, who account for 25% of revascularisation procedures, is much debated. We aimed to assess whether all-cause mortality differed between patients with diabetes who had CABG or PCI by doing a systematic review and meta-analysis of randomised controlled trials (RCTs) comparing CABG with PCI in the modern stent era.

01 octubre 2013

CIRCULATION. Physiological and Phenotypic Characteristics of Late Survivors of Tetralogy of Fallot Repair Who Are Free From Pulmonary Valve Replacement

Alessandra Frigiola, MD, MDres; Marina Hughes, DPhil, FRACP; Mark Turner, PhD, FRCP; Andrew Taylor, MD, MRCP, FRCR; Jan Marek, MD, PhD, FESC; Alessandro Giardini, MD; Tain-Yen Hsia, MD; Kate Bull, MRCP

Background—Pulmonary valve replacement (PVR) after repair of tetralogy of Fallot is commonly required and is burdensome. Detailed anatomic and physiologic characteristics of survivors free from late PVR and with good exercise capacity are not well described in a literature focusing on the indications for PVR.

01 octubre 2013

JACC: CARDIOVASCULAR INTERVENTIONS. First-in-Human Evaluation of a Bioabsorbable Polymer–Coated Sirolimus-Eluting StentImaging and Clinical Results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the Native Coronary Arteries)

John Ormiston, MB, ChB∗; Mark Webster, MB, ChB†; James Stewart, MB, ChB∗; Mathias Vrolix, MD‡; Robert Whitbourn, MBBS§; Dennis Donohoe, MD‖; Charlene Knape, MT‖; Alexandra Lansky, MD¶; Guilherme F. Attizzani, MD#; Peter Fitzgerald, MD, PhD∗∗; David E. Kandzari, MD††; William Wijns, MD, PhD‡‡

Objectives: This first-in-human multicenter study sought to examine prospectively the safety and efficacy of a new, cobalt chromium thin-strut, coronary absorbable polymer–coated, sirolimus-eluting stent.

01 octubre 2013

JACC. Predictors and Outcomes of Side Branch Occlusion After Main Vessel Stenting in Coronary Bifurcation LesionsResults From the COBIS II Registry (COronary BIfurcation Stenting)

Joo-Yong Hahn, MD, PhD∗; Woo Jung Chun, MD, PhD†; Ji-Hwan Kim, MD∗; Young Bin Song, MD, PhD∗; Ju Hyeon Oh, MD, PhD†; Bon-Kwon Koo, MD, PhD‡; Seung Woon Rha, MD, PhD§; Cheol Woong Yu, MD, PhD‖; Jong-Sun Park, MD, PhD¶; Jin-Ok Jeong, MD, PhD#; Seung-Hyuk Choi, MD, PhD∗; Jin-Ho Choi, MD, PhD∗; Myung-Ho Jeong, MD, PhD∗∗; Jung Han Yoon, MD, PhD††; Yangsoo Jang, MD, PhD‡‡; Seung-Jea Tahk, MD, PhD§§; Hyo-Soo Kim, MD, PhD‡; Hyeon-Cheol Gwon, MD, PhD∗

Objectives: This study sought to investigate the predictors and outcomes of side branch (SB) occlusion after main vessel (MV) stenting in coronary bifurcation lesions.